Anti CD19 Gene Therapy for B-cell Lymphoma

Summary

This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed/refractory B-cell lymphoma. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19 gene injection

Timeline

Start

2026-03-20

Primary completion

2029-12-31

Completion

2029-12-31

Drugs

Indications